The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Vaccination greatly reduces disease, disability, death and inequity worldwide
Open accessAbstract
In low-income countries, infectious diseases still account for a large proportion of deaths, highlighting health inequities largely caused by economic differences. Vaccination can cut health-care costs and reduce these inequities. Disease control, elimination or eradication can save billions of US dollars for communities and countries. Vaccines have lowered the incidence of hepatocellular carcinoma and will control cervical cancer. Travellers can be protected against "exotic" diseases by appropriate vaccination. Vaccines are considered indispensable against bioterrorism. They can combat resistance to antibiotics in some pathogens. Noncommunicable diseases, such as ischaemic heart disease, could also be reduced by influenza vaccination. Immunization programmes have improved the primary care infrastructure in developing countries, lowered mortality in childhood and empowered women to better plan their families, with consequent health, social and economic benefits. Vaccination helps economic growth everywhere, because of lower morbidity and mortality. The annual return on investment in vaccination has been calculated to be between 12% and 18%. Vaccination leads to increased life expectancy. Long healthy lives are now recognized as a prerequisite for wealth, and wealth promotes health. Vaccines are thus efficient tools to reduce disparities in wealth and inequities in health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Infectious Diseases of Humans: Dynamics and Control
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-2-174_4 · Cited by 7,746
Algebraic decay in hierarchical graphs
Garcia, A., Sonnino, G., Malek-Mansour, M.-A., & Baras, F. (1997) · doi:10.1023/a · Cited by 5,187
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Ruiz-Palacios, G. M., Pérez-Schael, I., Velázquez, F. R., Abate, H., Breuer, T., Clemens, S. C., Cheuvart, B., Espinoza, F., Gillard, P., Innis, B. L., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052434 · Cited by 1,799
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Poverty and health sector inequalities.
Wagstaff, A. R. (2002) · Europe PMC (PubMed Central) · Cited by 956
Cutts, F., Zaman, S., Enwere, G., Jaffar, S., Levine, O., Okoko, J., Oluwalana, C., Vaughan, A., Obaro, S., Leach, A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71876-6 · Cited by 900
Kyaw, M. H., Lynfield, R., Schaffner, W., Craig, A. S., Hadler, J., Reingold, A., Thomas, A. R., Harrison, L. H., Bennett, N. M., Farley, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051642 · Cited by 881
Nichol, K. L., Nordin, J., Mullooly, J., Lask, R., Fillbrandt, K., & Iwane, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025028 · Cited by 752
Active Bacterial Core Surveillance of the Emerging Infections Program Network
Schuchat, A., Hilger, T., Zell, E., Farley, M. M., Reingold, A., Harrison, L., Lefkowitz, L., Danila, R., Stefonek, K., Barrett, N., et al. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0701.010114 · Cited by 592
Cited by
Toll-like Receptors and the Control of Immunity
Fitzgerald, K. A., & Kagan, J. C. (2020) · Cell · doi:10.1016/j.cell.2020.02.041 · Cited by 2,168
The global burden of neurological disorders: translating evidence into policy
Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Deuschl, G., Parmar, P., Brainin, M., & Murray, C. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30411-9 · Cited by 1,303
Puri, N., Coomes, E. A., Haghbayan, H., & Gunaratne, K. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1780846 · Cited by 1,157
Attitudes to vaccination: A critical review
Yaqub, O., Castle-Clarke, S., Sevdalis, N., & Chataway, J. (2014) · Social Science & Medicine · doi:10.1016/j.socscimed.2014.04.018 · Cited by 1,089
Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19
Neumann-Böhme, S., Varghese, N. E., Sabat, I., Barros, P. P., Brouwer, W., van Exel, J., Schreyögg, J., & Stargardt, T. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01208-6 · Cited by 1,011
Vaccine hesitancy and healthcare providers
Paterson, P., Meurice, F., Stanberry, L. R., Glismann, S., Rosenthal, S. L., & Larson, H. J. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.042 · Cited by 897
Impact of Vaccines; Health, Economic and Social Perspectives
Rodrigues, C. M. C., & Plotkin, S. A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01526 · Cited by 737
Communicating with parents about vaccination: a framework for health professionals
Leask, J., Kinnersley, P., Jackson, C., Cheater, F., Bedford, H., & Rowles, G. (2012) · BMC Pediatrics · doi:10.1186/1471-2431-12-154 · Cited by 652
mRNA vaccines manufacturing: challenges and bottlenecks
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.038 · Cited by 545
“Vaccines are one of the greatest advances in medicine and an important public health tool, as they not only prevent infection, morbidity and mortality individually, but also reduce and eliminate disease prevalence locally, ultimately leading to eradication of disease globally [1].”
BackgroundUsing behavioral insights to increase vaccination policy effectiveness
Betsch, C., Böhm, R., & Chapman, G. B. (2015) · Policy Insights from the Behavioral and Brain Sciences · doi:10.1177/2372732215600716 · Cited by 378
Abbas, K., Procter, S. R., van Zandvoort, K., Clark, A., Funk, S., Mengistu, T., Hogan, D., Dansereau, E., Jit, M., Flasche, S., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30308-9 · Cited by 362
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development
Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00120 · Cited by 351
Immune-mediated approaches against COVID-19
Florindo, H. F., Kleiner, R., Vaskovich-Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi-Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 338
COVID-19 Vaccine–Related Discussion on Twitter: Topic Modeling and Sentiment Analysis
Lyu, J. C., Han, E. L., & Luli, G. K. (2021) · Journal of Medical Internet Research · doi:10.2196/24435 · Cited by 337
Li, X., Mukandavire, C., Cucunubá, Z. M., Echeverria Londono, S., Abbas, K., Clapham, H. E., Jit, M., Johnson, H. L., Papadopoulos, T., Vynnycky, E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32657-x · Cited by 300
Interventions for improving coverage of childhood immunisation in low- and middle-income countries
Oyo-Ita, A., Wiysonge, C. S., Oringanje, C., Nwachukwu, C. E., Oduwole, O., & Meremikwu, M. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008145.pub3 · Cited by 289
Lynn, D. J., Benson, S. C., Lynn, M. A., & Pulendran, B. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00554-7 · Cited by 289
Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic
Machida, M., Nakamura, I., Kojima, T., Saito, R., Nakaya, T., Hanibuchi, T., Takamiya, T., Odagiri, Y., Fukushima, N., Kikuchi, H., et al. (2021) · Vaccines · doi:10.3390/vaccines9030210 · Cited by 281
Vaccine hesitancy and perceived behavioral control: A meta-analysis
Xiao, X., & Wong, R. M. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.04.076 · Cited by 268
Quantitative measures of health policy implementation determinants and outcomes: a systematic review
Allen, P., Pilar, M., Walsh-Bailey, C., Hooley, C., Mazzucca, S., Lewis, C. C., Mettert, K. D., Dorsey, C. N., Purtle, J., Kepper, M. M., et al. (2020) · Implementation Science · doi:10.1186/s13012-020-01007-w · Cited by 164
Wakadha, H., Chandir, S., Were, E. V., Rubin, A., Obor, D., Levine, O. S., Gibson, D. G., Odhiambo, F., Laserson, K. F., & Feikin, D. R. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.11.093 · Cited by 149
Myocarditis following COVID-19 vaccination
Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021) · Radiology Case Reports · doi:10.1016/j.radcr.2021.05.033 · Cited by 127
“From Louis Pasteur, who developed the first laboratory vaccine in 1879, for chicken cholera[10], to the 21st century COVID-19 pandemic, untold disability and death has been prevented by vaccination[9].”
InfluentialRattray, N. J. W., Trivedi, D. K., Xu, Y., Chandola, T., Johnson, C. H., Marshall, A. D., Mekli, K., Rattray, Z., Tampubolon, G., Vanhoutte, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12716-2 · Cited by 101
Maternal vaccination: moving the science forward
Faucette, A. N., Unger, B. L., Gonik, B., & Chen, K. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu041 · Cited by 81
Sato, R. (2020) · Vaccine · doi:10.1016/j.vaccine.2019.09.097 · Cited by 26
Lutukai, M., Bunde, E. A., Hatch, B., Mohamed, Z., Yavari, S., Some, E., Chweya, A., Kania, C., Ross, J. C., Keddem, C., et al. (2019) · Global Health: Science and Practice · doi:10.9745/ghsp-d-19-00157 · Cited by 17
Proactive advising: a machine learning driven approach to vaccine hesitancy
Bell, A., Rich, A., Teng, M., Orešković, T., Bras, N. B., Mestrinho, L., Golubovic, S., Pristas, I., & Zejnilovic, L. (2019) · 2019 IEEE International Conference on Healthcare Informatics (ICHI) · doi:10.1109/ichi.2019.8904616 · Cited by 12
Metadata
- Authors
- Andre, F., Booy, R., Bock, H., Clemens, J., Datta, S., John, T., Lee, B., Lolekha, S., Peltola, H., Ruff, T., Santosham, M., & Schmitt, H.
- Venue
- Bulletin of the World Health Organization
- Publisher
- WHO Press
- Published
- 2008-02-01
- Volume
- 86
- Issue
- 2
- Pages
- 140-146
- ISSN
- 0042-9686 (ISSN-L)
- OpenAlex
- W2162555339
- Cited by
- 1,234
- References
- 54
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.